Verve Therapeutics Inc.

NASDAQ: VERV · Real-Time Price · USD
11.13
0.03 (0.27%)
At close: Jul 24, 2025, 3:59 PM

Verve Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
32.98M 13.08M 6.87M 6.69M 5.7M 5.14M 3.12M 2.09M 1.4M 1.01M 929K n/a n/a n/a n/a n/a n/a
Cost of Revenue
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Gross Profit
32.98M 13.08M 6.87M 6.69M 5.7M 5.14M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Income
-36.64M -56.07M -56.91M -58.84M -56.84M -53.95M -52.33M -58.58M -58.26M -47.71M -43.86M -42.19M -31.93M -32.54M -23.5M -16.96M -14.06M
Interest Income
5.46M n/a 6.89M 7.43M 8.14M n/a 5.84M 5.44M 5.55M n/a 1.98M 308K 82K n/a 53K 5K 20K
Pretax Income
-30.95M -49.96M -50.03M -49.74M -48.63M -48.32M -45.69M -53.81M -51.98M -41.03M -45.19M -40.95M -30.17M -31.34M -22.75M -52.97M -13.26M
Net Income
-31.03M -50.03M -50.13M -49.8M -48.74M -48.35M -45.76M -53.98M -45.69M -41.09M -46.52M -39.7M -28.41M -31.34M -22.75M -52.97M -13.26M
Selling & General & Admin
15.15M 14.1M 13.84M 14.55M 14.16M 12.28M 11.69M 13.42M 12.55M 11.44M 9.59M 9.07M 7.43M 6.6M 6.01M 3.54M 2.72M
Research & Development
54.46M 55.05M 49.94M 50.98M 48.38M 46.81M 43.77M 47.26M 47.11M 37.28M 35.2M 33.13M 24.49M 25.94M 17.5M 13.42M 11.35M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
69.61M 69.15M 63.77M 65.53M 62.54M 59.09M 55.45M 60.68M 59.66M 48.72M 44.79M 42.19M 31.93M 32.54M 23.5M 16.96M 14.06M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
69.61M 69.15M 63.77M 65.53M 62.54M 59.09M 55.45M 60.68M 59.66M 48.72M 44.79M 42.19M 31.93M 32.54M 23.5M 16.96M 14.06M
Income Tax Expense
79K 73K 104K 66K 106K 32K 67K 176K -6.28M 53K 1.33M -1.25M -1.76M n/a n/a n/a n/a
Shares Outstanding (Basic)
88.8M 86.87M 84.63M 84.23M 83.13M 69.67M 63.21M 61.95M 61.79M 61.46M 57.21M 48.67M 48.57M 48.03M 47.99M 47.95M 43.82M
Shares Outstanding (Diluted)
88.8M 86.87M 84.63M 84.23M 83.13M 69.67M 63.21M 61.95M 61.79M 61.46M 57.21M 48.67M 48.57M 48.03M 47.99M 47.95M 43.82M
EPS (Basic)
-0.35 -0.58 -0.59 -0.59 -0.59 -0.69 -0.72 -0.87 -0.74 -0.67 -0.81 -0.82 -0.58 -0.65 -0.47 -1.1 -0.3
EPS (Diluted)
-0.35 -0.58 -0.59 -0.59 -0.59 -0.69 -0.72 -0.87 -0.74 -0.67 -0.81 -0.82 -0.58 -0.65 -0.47 -1.1 -0.3
EBITDA
-34.92M -54.37M -55.16M -57.17M -55.21M -52.43M -50.86M -57.25M -57.13M -46.78M -43.14M -41.54M -31.41M -32.07M -23.09M -16.61M -13.77M
EBIT
-36.64M -56.07M -56.91M -58.84M -56.84M -53.95M -52.33M -58.58M -58.26M -47.71M -43.86M -42.19M -31.93M -32.54M -23.5M -16.96M -14.06M
Depreciation & Amortization
1.72M 1.7M 1.75M 1.67M 1.63M 1.52M 3.2M 3.03M 2.76M 2.55M 2M 1.15M 1.01M 969K 1.76M 357K 294K